Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States

References

• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010;62:1576-82
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum Dis 2010;69:1580-8
   PubMed Web of Science ®Google Scholar
• Prete M, Racanelli V, Digiglio L, et al. Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev 2011;11:123-31
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedvelt FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75
   PubMed Web of Science ®Google Scholar
• Matsumoto AK, Bathon J, Bingham CO III. Rheumatoid arthritis treatment. The Johns Hopkins Arthritis Center 2018. Available at: http://www.hopkinsarthritis.org/arthritis-info/rheumatoid-arthritis/ra-treatment/ [Last accessed August 2018]
   Google Scholar
• Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625-39
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions – United States, 2003. Morb Moral Wkly Rep 2007;56:4-7
   PubMedGoogle Scholar
• Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19
   PubMed Web of Science ®Google Scholar
• Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60
   PubMed Web of Science ®Google Scholar
• Kremer J, Li ZG, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med 2013;159:253-61
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70
   PubMed Web of Science ®Google Scholar
• Tofacitinib [prescribing information]. Pfizer, revised June 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/203214s010lbl.pdf [Last accessed September 2015]
   Google Scholar
• Bansback N, Ara R, Karnon J, Anis A. Economic evaluations in rheumatoid arthritis: a critical review of measures used to define health States. Pharmacoeconomics 2008;26:395-408
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Rheumatoid arthritis – adalimumab, etanercept, and infliximab. NICE technology appraisal guidance 130, 2011. Available at: https://www.nice.org.uk/guidance/ta130 [Last accessed September 2015]
   Google Scholar
• Vieira MC, Wallenstein GV, Bradley JD, et al. Tofacitinib versus biologic treatments with and without methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to traditional disease modifying anti-rheumatic drugs – a network meta-analysis. Ann Rheum Dis 2012;71(Suppl):375
   Google Scholar
• Rendas-Baum R, Wallenstein GV, Koncz T, et al. Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther 2011;13:R25
   PubMed Web of Science ®Google Scholar
• Borrud LG, Flegal KM, Looker AC, et al. Body composition data for individuals 8 years of age and older: US population 1999–2004, Vital Health Stat 2010;11:1-87
   Google Scholar
• Michaud K, Wallenstein G, Wolfe F. Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients. Arthritis Care Res (Hoboken) 2011;63:366-72
   PubMed Web of Science ®Google Scholar
• Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naïve and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012;71:1134-42
   PubMed Web of Science ®Google Scholar
• Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9
   PubMed Web of Science ®Google Scholar
• Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. Arthritis Rheum 2004;50:1400-11
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Baumgartner SW, Moreland LW, et al. Improvement in disability in rheumatoid arthritis patients with early vs established disease after treatment with etanercept. European League Against Rheumatism (EULAR) Annual Conference 2002, Stockholm, Sweden
   Google Scholar
• Emery P, Mease PJ, Rubbert-Roth A, et al. Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis. Rheumatology (Oxford) 2011;50:2223-32
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Tocilizumab for rheumatoid arthritis. NICE technology appraisal guidance 198, 2011. Available at: https://www.nice.org.uk/guidance/ta198 [Last accessed September 2015]
   Google Scholar
• Wollenhaupt J, Silverfield JC, Lee EB, et al. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, in the treatment of rheumatoid arthritis: open-label, long-term extension studies up to 36 months. Arthritis Rheum 2011;63(Suppl 10):S152
   Google Scholar
• Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther 2015;17:263
   PubMed Web of Science ®Google Scholar
• DMD America. AnalySource Online. 2014. Available at: https://www1.analysource.com/qry/as_menu.taf [Last accessed September 2015]
   Google Scholar
• Agency for Healthcare Research and Quality. Costs for Hospital Stays in the United States, 2010. 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb146.pdf [Last accessed September 2015]
   Google Scholar
• CMS. National Medicare Fee Schedule. Centers for Medicare and Medicaid Services, 2011
   Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62
   PubMed Web of Science ®Google Scholar
• Kawatkar AA, Jacobsen SJ, Levy GD, et al. Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey. Arthritis Care Res (Hoboken) 2012;64:1649-56
   PubMed Web of Science ®Google Scholar
• Emery P, Breedvelf FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82
   PubMed Web of Science ®Google Scholar
• Smolen JS, Nash P, Durez P, et al. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial . Lancet 2013;381:918-29
   PubMed Web of Science ®Google Scholar
• van Riel PL, Taggard AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006;65:1478-83
   PubMed Web of Science ®Google Scholar
• Yelin E, Trupin L, Wong B, Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002;29:1851-7
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-54
   PubMed Web of Science ®Google Scholar
• Malottki K, Barton P, Tsourapas A, et al. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation. Health Technol Assess 2011;15:1-278
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94
   PubMed Web of Science ®Google Scholar
• Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess 2004;8:iii, 1-91
   Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Deaths and Mortality. CDC, 2012
   Google Scholar
• Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-56
   PubMed Web of Science ®Google Scholar
• Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009;12:80-7
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72
   PubMed Web of Science ®Google Scholar